Side-by-side comparison of AI visibility scores, market position, and capabilities
$40M Series A. First patient dosed in Phase 1 for RLS-1496 — first GPX4 modulator targeting pathological senescent cells via ferroptosis. Novel senolytic mechanism.
Rubedo Life Sciences is a senolytic drug company that has advanced RLS-1496 into Phase 1 clinical trials — the first GPX4 (glutathione peroxidase 4) modulator designed to selectively eliminate pathological senescent cells through ferroptosis, a form of programmed cell death. The company has raised $40 million in Series A financing and dosed its first patient in June 2025, with a systemic formulation entering Phase 1 planned for 2026 that would dramatically broaden its clinical scope.
FY2025 (ended Mar 31, 2025): JPY 21.6887T (+6.2%) | Operating Profit: JPY 1.2134T (-12.2%) | FY2024: JPY 20.4286T (+20.8%) | Q3 FY2024 (9 months): Op Profit JPY 1.1399T, margin 7.0% | Auto sales down 297k (Asia impact) | FY2026 guidance: Net profit JPY 250B (-70.1%), Revenue JPY 20.3T (-6.4%)
Honda Motor Co., Ltd. is a Japanese multinational mobility conglomerate founded in 1948 by Soichiro Honda and Takeo Fujisawa in Hamamatsu, Japan. Starting as a motorcycle manufacturer, Honda expanded into automobiles, power equipment, marine engines, and aerospace, becoming one of the largest and most diversified mobility companies in the world. With over 90 million vehicles sold globally and a reputation built on engineering reliability, fuel efficiency, and innovation, Honda operates manufacturing facilities across more than 30 countries on six continents.\n\nHonda's automotive lineup ranges from mass-market sedans and SUVs — including the best-selling Civic and CR-V — to trucks, minivans, and the premium Acura brand. The company is executing a major pivot to electrification through the Honda 0 Series, a new EV architecture designed from the ground up for battery-electric vehicles launching in 2026. Honda's partnership with General Motors on battery technology, combined with its investment in solid-state battery development, reflects a multi-path electrification strategy designed to hedge technology risk while building scale.\n\nHonda reported FY2025 revenue of JPY 21.7 trillion, a 6.2% year-over-year increase, driven by strong North American demand and favorable currency tailwinds. The company faces intensifying competition from Chinese EV manufacturers in Asia and is exploring a potential merger with Nissan as part of broader Japanese automotive consolidation. Honda's engineering culture, global manufacturing scale, and brand credibility in reliability position it as a resilient and well-capitalized incumbent navigating the EV transition.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.